A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00897221

Enrollment

Registered

2009-05-12

Start date

2009-06-30

Completion date

2011-03-31

Last updated

2011-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Friedreich's Ataxia

Keywords

Friedreich's ataxia

Brief summary

The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia (FRDA). The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA. The tertiary objectives are to evaluate the effect of deferiprone on: 1. cardiac function, 2. quality of life, and 3. functional status.

Detailed description

This is a multi-centre, open-label, non-randomized, single treatment, safety and efficacy study. All subjects who completed the LA29-0207 study are eligible for participation. Participants will receive deferiprone oral solution at the same dose (20 or 40 mg/kg/day) that they were assigned for LA29-0207. The duration of treatment will be 52 weeks.

Interventions

DRUGDeferiprone oral solution 100mg/mL

Deferiprone oral solution (20 mg/kg/day)

DRUGDeferiprone oral solution 100 mg/mL

Deferiprone oral solution(40mg/kg/day)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Years to 35 Years

Healthy volunteers

Inclusion criteria

1. Subjects who completed the ApoPharma study LA29-0207 2. Female subjects of childbearing potential must have a negative pregnancy test. 3. Male subjects must confirm that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination. 4. Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedules.

Exclusion criteria

1. Serum Ferritin and Hemoglobin (Hb) levels are below the reference range for age and sex-matched controls. 2. Unable to complete T25FW AND with a score \> 5 minutes in the 9HPT. Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enrol). 3. Doubling of score on 9HPT or T25FW compared to their study baseline results in LA29-0207. 4. History or evidence of neutropenia/agranulocytosis defined by a confirmed absolute neutrophil count (ANC) \< 1.5 x 109/L or thrombocytopenia defined by a platelet count \<150 x 109/L. 5. Occurrence of SAEs or any other AEs during the LA29-0207 study, which in the opinion of the investigator cause the patient's participation in the extension study to be inappropriate. 6. Unable to comply with requirements of the protocol. 7. Pregnant, breastfeeding or planning to become pregnant during the study period. 8. QTc interval \>450ms. 9. Have been on antioxidants prior to start of study treatment.

Design outcomes

Primary

Measure	Time frame
The patient's long-term tolerance of treatment will be assessed by the occurence of adverse events.	52 weeks

Secondary

Measure	Time frame
The long-term efficacy of deferiprone will be assessed. Efficacy measures include the 9HPT, T25FW, LCLA, ICARS and FARS.	52 weeks

Countries

Belgium, France, Italy, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026